These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10551898)

  • 41. A cluster of positively charged amino acids in the alpha-chain of C4b-binding protein (C4BP) is pivotal for the regulation of the complement system and the interaction with bacteria.
    Blom AM
    Scand J Clin Lab Invest Suppl; 2000; 233():37-49. PubMed ID: 11317941
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunization against tumor cell surface complement-regulatory proteins.
    Durrant LG; Spendlove I
    Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Soluble complement component tackles reperfusion injury.
    Fricker J
    Mol Med Today; 1997 Oct; 3(10):413. PubMed ID: 9358464
    [No Abstract]   [Full Text] [Related]  

  • 44. Targeting the complement system.
    Marsh JE; Pratt JR; Sacks SH
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):557-62. PubMed ID: 10541217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of the complement system in antigen-induced bronchoconstriction and changes in blood pressure in the guinea pig.
    Regal JF; Fraser DG; Toth CA
    J Pharmacol Exp Ther; 1993 Nov; 267(2):979-88. PubMed ID: 8246173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complement and the central nervous system: emerging roles in development, protection and regeneration.
    Rutkowski MJ; Sughrue ME; Kane AJ; Mills SA; Fang S; Parsa AT
    Immunol Cell Biol; 2010; 88(8):781-6. PubMed ID: 20404838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [New complement inhibitors; synthetic and natural products].
    Gancevici GG; Popescu C
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1985; 30(3):263-75. PubMed ID: 4048755
    [No Abstract]   [Full Text] [Related]  

  • 48. Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization.
    Li Y; Johnson JB; Parks GD
    Virology; 2016 Oct; 497():305-313. PubMed ID: 27505156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts.
    Lam TT; Hausen B; Hook L; Lau M; Higgins J; Christians U; Jacobsen W; Baluom M; Duthaler R; Katopodis A; Chavez G; Cozzi E; Harrison R; Schuurman HJ; Borie D; Morris RE
    Xenotransplantation; 2005 Jan; 12(1):20-9. PubMed ID: 15598270
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic potential of targeting the complement cascade in critical care medicine.
    Bhole D; Stahl GL
    Crit Care Med; 2003 Jan; 31(1 Suppl):S97-104. PubMed ID: 12544983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Creation of synthetic serine proteinase inhibitors, an important pharmacological problem].
    Markwardt F
    Farmakol Toksikol; 1978; 41(5):530-3. PubMed ID: 359347
    [No Abstract]   [Full Text] [Related]  

  • 52. Membrane complement regulatory proteins.
    Kim DD; Song WC
    Clin Immunol; 2006; 118(2-3):127-36. PubMed ID: 16338172
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-inflammatory drugs and the complement system. A condensation product of metacresolsulfonic acid and formaldehyde prevents instantly the complement activation in vitro.
    Gancevici GG; Popescu C
    Arch Roum Pathol Exp Microbiol; 1989; 48(2):157-62. PubMed ID: 2634368
    [No Abstract]   [Full Text] [Related]  

  • 54. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
    Risitano AM; Marotta S
    Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complement activation and inhibition in myocardial ischemia and reperfusion injury.
    Homeister JW; Lucchesi BR
    Annu Rev Pharmacol Toxicol; 1994; 34():17-40. PubMed ID: 8042849
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat.
    Pratt JR; Hibbs MJ; Laver AJ; Smith RA; Sacks SH
    Am J Pathol; 1996 Dec; 149(6):2055-66. PubMed ID: 8952538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heparin treatment in pregnancy loss: Potential therapeutic benefits beyond anticoagulation.
    Girardi G
    J Reprod Immunol; 2005 Jun; 66(1):45-51. PubMed ID: 15949561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia.
    Fujita Y; Inoue I; Inagi R; Miyata T; Shinzato T; Sugiyama S; Miyama A; Maeda K
    Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):393-7. PubMed ID: 8341019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Continuous complement (C) inhibition using soluble C receptor type 1 (sCR1): effect on hyperacute rejection (HAR) of pig-to-primate cardiac xenografts.
    Pruitt Sk; Bollinger RR; Collins BH; Marsh HC; Levin JL; Rudolph AR; Baldwin WM; Sanfilippo F
    Transplant Proc; 1996 Apr; 28(2):756. PubMed ID: 8623382
    [No Abstract]   [Full Text] [Related]  

  • 60. Tailoring anti-complement therapeutics.
    Harris CL; Fraser DA; Morgan BP
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):1019-26. PubMed ID: 12440965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.